All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Cedars-Sinai Medical Center Paul W Noble Basic Biology V Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $617,662
Gladstone Institutes, J. David Sheng Ding PhD Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,294,495
University of California, San Francisco Dr. Mark S. Anderson Basic Biology V Generation of a functional thymus to induce immune tolerance to stem cell derivatives $1,191,000
University of California, Irvine Dr. Lisa A Flanagan Basic Biology V Molecular basis of plasma membrane characteristics reflecting stem cell fate potential $994,108
University of California, San Diego Maike Sander Basic Biology V Defining links between chromatin state and developmental competence $1,050,300
University of Southern California Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $735,138
University of California, Los Angeles Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $411,330
University of California, San Diego Miles F Wilkinson Basic Biology V New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors $552,811
University of California, Los Angeles Dr. Lili Yang Basic Biology V Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400
University of California, San Diego Dr. Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,160,997
University of California, San Diego Dr. Wei Wang Basic Biology V Systems-level discovery of the regulatory mechanisms directing differentiation of hESC $1,161,000
University of California, San Diego Dr. Lawrence S. B. Goldstein Basic Biology V Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes $1,050,300
University of California, San Diego Dr. David A. Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, Berkeley Dr. Andrew Dillin Basic Biology V A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health $1,034,100
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
University of Southern California Dr. Mark S Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Davis Dr. Peter C. Belafsky Disease Team Therapy Development III Tissue Engineered Recellularized Laryngotracheal Implants $3,181,162
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
Stanford University Dr. Irving L Weissman MD Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, Los Angeles Dr. Donald B. Kohn Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $13,145,465
University of California, San Diego Thomas J Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) $4,179,598
Sangamo BioSciences, Inc. Dr. Fyodor D Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
Human BioMolecular Research Institute Dr. John R Cashman Patent Assistance Fund Awards Intellectual Property for Stem Cell-Related Inventions – HBRI $50,000
University of California, San Francisco Karin Immergluck PhD Patent Assistance Fund Awards Patent Assistance Fund Proposal – UCSF $87,257
University of California, Davis David McGee Patent Assistance Fund Awards CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies – UCD $48,595
University of California, Santa Barbara Bernadette McCafferty Patent Assistance Fund Awards Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. $23,564
University of California, Irvine Ronnie Hanecak Patent Assistance Fund Awards CIRM Patent Assistance Fund Application – UCI $46,155
University of California, Los Angeles Adele Rennie Patent Assistance Fund Awards Patent Assistance Fund – UCLA $84,973
Stanford University Katharine Ku Patent Assistance Fund Awards Funding for Patent Applications for CIRM-funded Inventions out of Stanford University $3,525
University of California, San Diego Dr. Rubén D. Flores Patent Assistance Fund Awards Patent Assistance Fund Application – UCSD $38,162
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
University of California, Los Angeles Dr. Irvin SY Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, Los Angeles Dr. Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
University of California, Los Angeles Dr. Robert Reiter MD Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
Human BioMolecular Research Institute Dr. John R Cashman Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Numerate, Inc. Dr. John H Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $520,015
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
University of California, Los Angeles Dr. Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
University of California, Los Angeles Dr. Donald B. Kohn Early Translational IV Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,651,884
Salk Institute for Biological Studies Dr. Inder M. Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
The Scintillon Institute Dr. Stuart A Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,103,185
Sanford Burnham Prebys Medical Discovery Institute Dr. Stuart A Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,020,815
University of California, San Diego Professor Alysson R Muotri Early Translational IV A drug-screening platform for autism spectrum disorders using human astrocytes $1,656,456
Cedars-Sinai Medical Center Dr. Dan Gazit Early Translational IV Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,121,514
Stanford University Dr. Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
Gladstone Institutes, J. David Dr. Steve M. Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,049,053
University of California, Irvine Dr. Magdalene J Seiler Early Translational IV Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
ViaCyte, Inc. Howard Foyt Strategic Partnership I Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $9,475,070
Bluebird Bio David M. Davidson Strategic Partnership I A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells Transduced with the Lentiviral Vector LentiGlobin® Encoding the Human β-A-T87Q-… $0
FUJIFILM Cellular Dynamics Deborah Requesens hPSC Repository The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs $9,942,175